Characterization of a Bivalent Vaccine Capable of Inducing Protection Against Both Ebola and Cross-clade H5N1 Influenza in Mice

Journal of Infectious Diseases

Volumn 212, Issue , 2015, Pages S435-S442

  Wong, Gary ^a,b   Qiu, Xiangguo ^a,b   Ebihara, Hideki ^c   Feldmann, Heinz ^b,c   Kobinger, Gary P ^a,b,d  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ebola virus; H5N1 influenza virus; mice; vaccine; vesicular stomatitis virus

Indexed keywords

INFLUENZA A VIRUS (A/HANOI/30408/2005(H5N1))HEMAGGLUTININ; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT VACCINE; RECOMBINANT VESICULAR STOMATITIS VIRUS HEMAGGLUTININ EBOLA VIRUS GLYCOPROTEIN; UNCLASSIFIED DRUG; HEMAGGLUTININ; VIRUS ANTIBODY; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; EVOLUTIONARY HOMOLOGY; FEMALE; HETEROLOGOUS IMMUNITY; HUMORAL IMMUNITY; IMMUNIZATION; INFANT; INFLUENZA A (H5N1); INFLUENZA A VIRUS (H5N1); LIMIT OF DETECTION; MONITORING; MOUSE; NONHUMAN; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT DURATION; VACCINATION; VIRUS STRAIN; WEIGHT REDUCTION; ANIMAL; BAGG ALBINO MOUSE; CHLOROCEBUS AETHIOPS; CROSS PROTECTION; DOG; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; INFLUENZA; MDCK CELL LINE; ORTHOMYXOVIRUS INFECTION; PROCEDURES; VERO CELL LINE; VESICULOVIRUS;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CROSS PROTECTION; DOGS; EBOLAVIRUS; FEMALE; HEK293 CELLS; HEMAGGLUTININS; HEMORRHAGIC FEVER, EBOLA; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION; VERO CELLS; VESICULOVIRUS; VIRAL VACCINES;

EID: 84943239021     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv257     Document Type: Article

References (37)

1. Feldmann H, Sanchez A, Geisbert TW. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley P, eds. Fields Virology. Philadelphia, PA, USA: Lippincott Williams and Wilkins, 2013.
2. Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature 2005; 438:575-6.
3. WHO.int. Ebola Situation Report. 22 April 2015. http://apps.who.int/ ebola/current-situation/ebola-situation-report-22-april-2015-0. Accessed 23 April 2015.
4. Schwartz JA, Buonocore L, Suguitan AL Jr, et al. Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge. J Virol 2010; 84:4611-8.
5. Alexander DJ, Brown IH. Recent zoonoses caused by influenza A viruses. Rev Sci Tech 2000; 19:197-225.
6. WHO. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. WHO, 2011.
7. Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis 1999; 180:505-8.
8. Suarez DL, Perdue ML, Cox N, et al. Comparisons of highly virulent H5N1 influenza A viruses isolated from humans and chickens from Hong Kong. J Virol 1998; 72:6678-88.
9. Chen H, Smith GJ, Li KS, et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci USA 2006; 103:2845-50.
10. Li KS, Guan Y,Wang J, et al. Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia. Nature 2004; 430:209-13.
11. Neumann G, Chen H, Gao GF, Shu Y, Kawaoka Y. H5N1 influenza viruses: outbreaks and biological properties. Cell Res 2010; 20:51-61.
12. Butler D. Family tragedy spotlights flu mutations. Nature 2006; 442: 114-5.
13. Normile D. Avian influenza. Human transmission but no pandemic in Indonesia. Science 2006; 312:1855.
14. WHO. Updated unified nomenclature system for the highly pathogenic H5N1 avian influenza viruses. WHO, 2011.
15. Richardson JS, Yao MK, Tran KN, et al. Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLOS One 2009; 4:e5308.
16. Ao Z, Patel A, Tran K, et al. Characterization of a trypsin-dependent avian influenza H5N1-pseudotyped HIV vector system for high throughput screening of inhibitory molecules. Antiviral Res 2008; 79:12-8.
17. Schnell MJ, Buonocore L, Whitt MA, Rose JK. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 1996; 70:2318-23.
18. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 1998; 178:651-61.
19. Reed LV, Muench H. A simple method of estimating fifty per cent end points. Am J Hyg 1938; 27:493-7.
20. Nakayama E, Yokoyama A, Miyamoto H, et al. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin Vaccine Immunol 2010; 17:1723-8.
21. Jones SM, Feldmann H, Stroher U, et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med 2005; 11:786-90.
22. Ryder AB, Buonocore L, Vogel L, Nachbagauer R, Krammer F, Rose JK. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza hemagglutinin and neuraminidase is a potent influenza vaccine. J Virol 2015; 89:2820-30.
23. Kapadia SU, Rose JK, Lamirande E, Vogel L, Subbarao K, Roberts A. Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology 2005; 340:174-82.
24. Tsuda Y, Safronetz D, Brown K, et al. Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection. J Infect Dis 2011; 204(suppl 3):S1090-7.
25. Feldmann H, Jones SM, Daddario-DiCaprio KM, et al. Effective postexposure treatment of Ebola infection. PLOS Pathog 2007; 3:e2.
26. Wong G, Audet J, Fernando L, et al. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Vaccine 2014; 32:5722-9.
27. Mire CE, Geisbert JB, Agans KN, et al. Durability of a vesicular stomatitis virus-based Marburg virus vaccine in nonhuman primates. PLOS One 2014; 9:e94355.
28. Geisbert TW, Daddario-Dicaprio KM, Lewis MG, et al. Vesicular stomatitis virus-based Ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates. PLOS Pathog 2008; 4:e1000225.
29. WHO.int. WHO Meeting of the Scientific and Technical Advisory Committee on Ebola Experimental Interventions-Briefing note. http://www.who.int/medicines/ebola-treatment/scientific-tech-meeting/ en/#. Accessed 15 January 2015.
30. Patel A, Tran K, Gray M, et al. Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine 2009; 27:3083-9.
31. Wrammert J, Koutsonanos D, Li GM, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011; 208:181-93.
32. Mallajosyula VV, Citron M, Ferrara F, et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci USA 2014; 111: E2514-23.
33. Foy HM, Allan I, Blumhagen JM, Cooney MK, Hall C, Fox JP. A/USSR and B/Hong Kong vaccine. Field experiences during an A/Brazil and an influenza B epidemic. JAMA 1981; 245:1736-40.
34. Villarreal LP, Breindl M, Holland JJ. Determination of molar ratios of vesicular stomatitis virus induced RNA species in BHK21 cells. Biochemistry 1976; 15:1663-7.
35. Olinger GG Jr, Pettitt J, Kim D, et al. Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci USA 2012; 109:18030-5.
36. Qiu X, Audet J, Wong G, et al. Successful treatment of Ebola virus-infected cynomolgus macaques with monoclonal antibodies. Sci Transl Med 2012; 4:138ra81.
37. Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 2014; 514:47-53.